2. Search Result
Search Result
Results for "

hepatic bile acid

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

9

Natural
Products

3

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13771A
    Ursodeoxycholic acid sodium
    Maximum Cited Publications
    16 Publications Verification

    Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium

    		 G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite Metabolic Disease Inflammation/Immunology Cancer
    Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
    Ursodeoxycholic acid sodium
  • HY-13771
    Ursodeoxycholic acid
    Maximum Cited Publications
    16 Publications Verification

    Ursodeoxycholate; Ursodiol; UDCA

    		 G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Infection Metabolic Disease Cancer
    Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
    Ursodeoxycholic acid
  • HY-W779068
    Chenodeoxycholic acid 3-sulfate disodium

    		Endogenous Metabolite Inflammation/Immunology
    Chenodeoxycholic acid 3-sulfate disodium is a bile acid. Chenodeoxycholic acid 3-sulfate disodium level corresponds closely with the extent of hepatic dysfunction .
    Chenodeoxycholic acid 3-sulfate disodium
  • HY-113315
    3b-Hydroxy-5-cholenoic acid

    		Endogenous Metabolite Metabolic Disease
    3b-Hydroxy-5-cholenoic acid is a monohydroxy bile acid of endogenous origin. 3b-Hydroxy-5-cholenoic acid can be used in the study of hepatic ductular hypoplasia syndrome .
    3b-Hydroxy-5-cholenoic acid
  • HY-113360
    Chenodeoxycholic acid 3-sulfate

    		Endogenous Metabolite Inflammation/Immunology
    Chenodeoxycholic acid 3-sulfate is a bile acid. Chenodeoxycholic acid 3-sulfate level corresponds closely with the extent of hepatic dysfunction .
    Chenodeoxycholic acid 3-sulfate
  • HY-176305S
    Neurofilament, U-15N

    		Isotope-Labeled Compounds Neurological Disease
    Neurofilament, U- 15N is the 15N-labeled Neurofilament.
    Neurofilament, U-15N
  • HY-13771R
    Ursodeoxycholic acid (Standard)

    Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)

    		 Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Infection Metabolic Disease Cancer
    Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
    Ursodeoxycholic acid (Standard)
  • HY-168524
    SOAT-IN-1

    		Na+/HCO3- Cotransporter Cancer
    SOAT-IN-1 (compound 40) is a potent and selective sodium-dependent organic anion transporter (SOAT) inhibitor with IC50 values of 1.6, 14.3 µM for SOAT, NTCP, respectively .
    SOAT-IN-1
  • HY-105047
    Fluorescein lisicol

    NRL972

    		 Biochemical Assay Reagents Metabolic Disease
    Fluorescein lisicol is a fluorescent-labelled bile salt and a marker of hepatic biliary transporter function. Fluorescein lisicol can be used for metabolic research .
    Fluorescein lisicol
  • HY-169799
    Cholylglycylamidofluorescein

    CGamF

    		 Endogenous Metabolite Fluorescent Dye Metabolic Disease
    Cholylglycylamidofluorescein (CGamF) is a fluorescent probe for hepatic bile acid transport. Cholylglycylamidofluorescein is composed of Cholic acid conjugated via a glycylamino linkage to fluorescein. (Ex/Em = 492/515 nM in Aqueous)
    Cholylglycylamidofluorescein
  • HY-113478
    3β-Ursodeoxycholic acid
    1 Publications Verification

    Isoursodeoxycholic acid

    		 Drug Metabolite Metabolic Disease
    3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid. 3β-Ursodeoxycholic acid shows good tolerance and well intestinal absorption by oral adminstation. 3β-Ursodeoxycholic acid can be isomerized by intestinal and hepatic enzymes to yield UDCA .
    3β-Ursodeoxycholic acid
  • HY-13771S1
    Ursodeoxycholic acid-13C

    Ursodeoxycholate-13C; Ursodiol-13C; UDCA-13C

    		 Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite Cancer
    Ursodeoxycholic acid- 13C is the 13C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
    Ursodeoxycholic acid-13C
  • HY-129982
    SC-435

    		Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .
    SC-435
  • HY-113478S
    Ursodeoxycholic acid-2,2,4,4-d4

    		Isotope-Labeled Compounds Infection Metabolic Disease
    Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .
    Ursodeoxycholic acid-2,2,4,4-d4
  • HY-113478R
    3β-Ursodeoxycholic acid (Standard)

    Isoursodeoxycholic acid (Standard)

    		 Drug Metabolite Reference Standards Metabolic Disease
    3β-Ursodeoxycholic acid (Standard) is the analytical standard of 3β-Ursodeoxycholic acid. This product is intended for research and analytical applications. 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid. 3β-Ursodeoxycholic acid shows good tolerance and well intestinal absorption by oral adminstation. 3β-Ursodeoxycholic acid can be isomerized by intestinal and hepatic enzymes to yield UDCA .
    3β-Ursodeoxycholic acid (Standard)
  • HY-N13208
    Stevia Powder

    		MMP TGF-beta/Smad Others
    Stevia Powder is a natural sweetener with antioxidant activity. Stevia Powder can downregulate pro fibrotic pathways in cirrhotic rats, including reduced hepatic myofibroblasts and decreased expression of matrix metalloproteinases MMP2 and MMP13, upregulate anti fibrotic molecule Smad7, prevent serum necrosis and elevated bile stasis markers, thereby inhibiting the development of liver fibrosis .
    Stevia Powder
  • HY-B1282AR
    Sulfaquinoxaline sodium salt (Standard)

    		Reference Standards Bacterial Parasite Antibiotic Infection
    3β-Ursodeoxycholic acid (Standard) is the analytical standard of 3β-Ursodeoxycholic acid. This product is intended for research and analytical applications. 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid. 3β-Ursodeoxycholic acid shows good tolerance and well intestinal absorption by oral adminstation. 3β-Ursodeoxycholic acid can be isomerized by intestinal and hepatic enzymes to yield UDCA .
    Sulfaquinoxaline sodium salt (Standard)
  • HY-113315R
    3b-Hydroxy-5-cholenoic acid (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    3b-Hydroxy-5-cholenoic acid (Standard) is an analytical standard for 3b-Hydroxy-5-cholenoic acid. This product is intended for research and analytical applications. 3b-Hydroxy-5-cholenoic acid is a monohydroxy bile acid of endogenous origin. 3b-Hydroxy-5-cholenoic acid can be used in the study of hepatic ductular hypoplasia syndrome .
    3b-Hydroxy-5-cholenoic acid (Standard)
  • HY-B1907A
    Rifamycin

    Rifamycin SV

    		 Antibiotic Bacterial DNA/RNA Synthesis Infection Inflammation/Immunology
    Rifamycin (Rifamycin SV) is an orally active ansamycin antibiotic. Rifamycin inhibits DNA-dependent RNA synthesis. Rifamycin has antibacterial activity against Mycobacterium tuberculosis. Rifamycin interferes with hepatic bile acid metabolism. Rifamycin has anti-inflammatory effects. Rifamycin can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .
    Rifamycin
  • HY-B1907
    Rifamycin sodium

    Rifamycin SV sodium

    		 Antibiotic Bacterial DNA/RNA Synthesis Infection Inflammation/Immunology
    Rifamycin sodium (Rifamycin SV monosodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .
    Rifamycin sodium
  • HY-B1907R
    Rifamycin sodium (Standard)

    Rifamycin SV sodium (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Rifamycin (sodium) (Standard) is the analytical standard of Rifamycin (sodium). This product is intended for research and analytical applications. Rifamycin sodium (Rifamycin SV sodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .
    Rifamycin sodium (Standard)
  • HY-W018791
    Bifendate
    1 Publications Verification

    DDB

    		 HBV Autophagy Cytochrome P450 Atg8/LC3 p62 P-glycoprotein Infection Cardiovascular Disease Cancer
    Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .
    Bifendate
  • HY-N0322B
    Cholesterol (Excipient, GMP Like)

    		Liposome Endogenous Metabolite Others
    Cholesterol (Excipient, GMP Like) is the GMP Like class Cholesterol (HY-N0322), and can be used as pharmaceutical excipients. Cholesterol is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity. In Vitro: Cholesterol (200 μg/mL; 40 h) increases the production of newly synthesized β-amyloid protein and enhances the secretion of Aβ1-40 in HEK cells transfected with APP . In Vivo: Cholesterol (0.5% cholesterol in diet; oral; once daily; 7 days) increases plasma cholesterol in the hamster model, while the cholesterol absorption inhibitor SCH 48461 (10 mg/kg; oral gavage; once daily; 7 days) inhibits cholesterol absorption and reduces plasma cholesterol .
    Cholesterol (1% cholesterol + 0.5% bile acid in diet; oral; once daily; 7 days) increases plasma cholesterol levels in the male CD rat model, while SCH 48461 (2 mg/kg; oral; once daily; 7 days) reduces hepatic cholesterol ester accumulation .
    Cholesterol (0.25% cholesterol + 22% saturated fat diet; oral; once daily; 3 weeks) increases VLDL+LDL cholesterol levels in the rhesus monkey model, while SCH 48461 (0.2 mg/kg; oral; once daily; 3 weeks) maintains baseline levels and inhibits cholesterol absorption .
    Cholesterol (Excipient, GMP Like)
  • HY-134988
    EDP-305

    		FXR Phosphatase Cytochrome P450 Inflammation/Immunology
    EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
    EDP-305

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: